As the field of personalized immunotherapy progresses, comprehensive genomic profiling, including screening for POLE mutations and their co‐occurring mutations like KIF16B, should be integrated into CRC management, particularly for hypermutated MSS tumors with no other actionable alterations. Here, KIF16B is linked to colorectal carcinoma.